Granzyme B is important for the ability of NK cells and CD8 + T cells to kill their targets. However, we showed here that granzyme Bdeficient mice clear both allogeneic and syngeneic tumor cell lines more efficiently than do wild-type (WT) mice. To determine whether regulatory T (Treg) cells utilize granzyme B to suppress immune responses against these tumors, we examined the expression and function of granzyme B in Treg cells. Granzyme B was not expressed in naive Treg cells but was highly expressed in 5%-30% of CD4 + Foxp3 + Treg cells in the tumor environment. Adoptive transfer of WT Treg cells, but not granzyme B-or perforin-deficient Treg cells, into granzyme B-deficient mice partially restored susceptibility to tumor growth; Treg cells derived from the tumor environment could induce NK and CD8 + T cell death in a granzyme B-and perforin-dependent fashion. Granzyme B and perforin are therefore relevant for Treg cell-mediated suppression of tumor clearance in vivo.
INTRODUCTION
Many studies have established that cell-mediated innate and adaptive immunity are essential for preventing primary tumor outgrowth and for rejecting transplanted tumors (Dunn et al., 2004a; Pardoll, 2003) . Natural killer (NK) cells are innate immune effectors that can kill MHC class I-deficient (MHC I -) tumor cell lines in vivo (Karre et al., 1986; Smyth et al., 2000a) . Mice genetically deficient for NK cells display severe defects in the clearance of MHC I -tumor cells (Kim et al., 2000) . In addition, mice depleted of NK cells are more susceptible to chemically induced tumors (Smyth et al., 2001) . Adoptive transfer studies have established that CD8 + T cells, as major effectors for antigen-specific antitumor immunity, can recognize and kill malignant cells that present antigen peptides with MHC I molecules (Gorelik and Flavell, 2001; Okada et al., 1997) . At the molecular level, the granule exocytosis pathway and Fas-FasL system account for virtually all of the measurable contact-mediated cytotoxicity delivered by NK and CD8 + T cells (Lieberman, 2003; Russell and Ley, 2002) . The granule exocytosis pathway utilizes perforin to traffic granzymes appropriately into the cytosol (Keefe et al., 2005; Shi et al., 1997) , where granzymes A and B (and orphan granzymes) induce cell death by cleaving critical substrates (Heusel et al., 1994; Lieberman, 2003; Revell et al., 2005; Russell and Ley, 2002) . Perforin-deficient (Prf1 À/À ) mice are more susceptible to the development of spontaneous lymphomas (Smyth et al., 2000b) , suggesting that the perforin-granzyme pathway is an important component of tumor surveillance.
Despite the fact that activated immune cells exist in cancer patients, the immune system often fails to prevent tumors and limit their spread (Dunn et al., 2004b) . Thus, established tumors must have developed strategies to inhibit or evade the immune system. Sakaguchi and colleagues first established the essential role of CD4 + CD25 + regulatory T (Treg) cells in the induction and maintenance of peripheral tolerance to self-antigens (Sakaguchi, 2004; Sakaguchi et al., 1995; Yamaguchi and Sakaguchi, 2006) . More recent studies have implicated Treg cells in inducing tolerance to tumors (von Boehmer, 2005; Yamaguchi and Sakaguchi, 2006; Zou, 2006) . For example, adoptively transferred Treg cells can inhibit tumor-specific CD8 + T cell-mediated immunity (Antony et al., 2005; Turk et al., 2004) . Furthermore, Treg cells have been shown to suppress NK cell-mediated rejection of transplanted tumor cells or bone-marrow grafts (Barao et al., 2006; Ghiringhelli et al., 2005) .
Treg cells may use the perforin-granzyme pathway as a mechanism to suppress the function of immune cells by killing them. Grossman et al. demonstrate that activated human Treg cells expressed granzyme A and/or B and could kill various autologous immune cells in a perforin-dependent but FasL-independent fashion (Grossman et al., 2004a) . In addition, Zhao et al. report that activated murine Treg cells suppressed B cell proliferation in a granzyme B-and perforin-dependent fashion (Zhao et al., 2006) , whereas Gondek et al. report that activated murine Treg cells suppressed CD4 + CD25 À T effector cells via a granzyme B-dependent, but perforin-independent, mechanism (Gondek et al., 2005) . Importantly, all of these studies utilized in vitro methods to activate Treg cells. It is not yet clear whether Treg cells activated in vivo express granzymes, and if so, whether these molecules are important for Treg cell-mediated suppression of antitumor immune responses.
In this study, we examined the roles of perforin and granzymes for tumor clearance in congenic 129/SvJ mice, by using RMAS lymphoma and B16 melanoma cell lines (both derived from B6 mice) and an acute myeloid leukemia (AML) 
RESULTS

Gzmb
À/À Mice Clear Allogeneic Tumor Cells More
Efficiently than Do WT Mice The RMAS lymphoma and B16 melanoma cell lines were derived from C57BL/6 (B6) mice (H-2 b , I-A b ) and express very low amounts of MHC class I and no detectable MHC class II ( Figure S1A in the Supplemental Data available online). NK cell-deficient B6 mice have defects in clearing RMAS and B16 cells (Kim et al., 2000) . Because all of our granzyme mutations were made and maintained in congenic 129/SvJ mice (also H-2 b , I-A b ), we first evaluated whether the minor histocompatibility differences between the B6-derived RMAS and B16 cell lines and the 129/SvJ mice would affect the ability of these cell lines to be cleared in an NK cell-dependent fashion. By using a well-established strategy to deplete NK cells by intravenous (i.v.) injection of anti-asialo GM1 antiserum, we determined that clearance of both RMAS and B16 tumor cells in the pure 129/SvJ strain is NK cell dependent (Figures S1B and S1C) . However, CD8 + T cell-depleted mice also displayed reduced survival after RMAS challenge ( Figure S1B ), suggesting that minor histocompatibility differences can induce CD8 + T cell-mediated clearance of these tumor cells.
To define the roles of perforin and granzymes for the clearance of these cell lines, several doses of RMAS cells were used to challenge the mice. The survival curves after i.v. injection of 1 3 10 5 and 2 3 10 5 RMAS cells are shown in Figures 1A and 1B (B) Kaplan-Meier survival curves of 129/SvJ WT mice versus mice deficient for the indicated granzymes or perforin, after intravenous injection with 2 3 10 5 RMAS lymphoma cells (LD50 for WT mice).
(C) Kaplan-Meier survival curves of 129/SvJ WT mice versus mice deficient for the indicated granzymes or perforin, after intravenous injection of 3 3 10 5 B16 melanoma cells (LD50 for WT mice).
of WT mice. Surprisingly, Gzmb À/À mice were significantly more resistant to RMAS cells than did WT mice (p < 0.01; Figures 1A and 1B) . Similar patterns were found with mice challenged with 3 3 10 5 B16 cells ( Figure 1C) Figure S2 and data not shown). Within the CD8 + T cell compartment, neither granzyme A nor B was detected before tumor challenge; both were detected in 10%-50% of CD8 + T cells found in the tumor environments 4-14 days after tumor challenge ( Figure S3 and data not shown). Because Gzma
Gzmb À/À mice were more susceptible than WT mice to these tumors (Figure 1 ), these data suggest that NK and/or CD8 + T cells utilize granzymes A and B to clear these tumor cells in vivo. Recent data from our laboratory, using in vitro activated NK cells derived from the same mouse strains, are consistent with these findings (Fehniger et al., 2007) .
Granzyme B Is Expressed in Allogeneic
Tumor-Activated Treg Cells Previously, our laboratory demonstrated that activated human Treg cells can use the perforin-granzyme pathway to kill a variety of autologous immune cells in vitro (Grossman et al., 2004a) . To explain the increased survival of Gzmb À/À mice challenged with RMAS or B16 tumor cells, we hypothesized that these tumor cells may induce granzyme B expression in Treg cells, which in turn utilize this enzyme to suppress the NK and CD8 + T cells that are responsible for clearing these tumors. To test this hypothesis, we assessed the impact of Treg cell depletion with a CD25 antibody (PC61) injected before the tumor challenge. Treg cell-depleted mice cleared RMAS cells more efficiently than did mice treated with an isotype control ( Figure 2A ).
In addition, we used flow cytometry to evaluate granzyme expression in CD4 + Foxp3 + Treg cells (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003) isolated directly from the tumor environments (ascites fluid after i.p. injection or tumor-infiltrated livers and/or lungs after i.v. injection). Granzyme B, but not granzyme A, was detected in 5%-30% of CD4 + Foxp3 + Treg cells found in the ascites fluid of mice bearing RMAS tumor cells for 4-14 days ( Figures 2B and 2C) ; very similar granzyme B expression patterns were found in the Treg cells in tumor-infiltrated livers and/or lungs after i.v. injection with RMAS or B16 cells (data not shown). In contrast, very few granzyme B-expressing Treg cells were found in the spleens ( Figure S4 ) or peripheral lymph nodes of tumor-bearing mice, or in the spleens, livers, or lungs of naive mice (<1%, data not shown). To confirm these flow cytometry results, we purified Treg cells from the ascites fluid of RMAS tumor-injected mice and performed immunofluorescence (IF) studies. Granzyme B was detected in the granules of Treg cells derived from the tumor ascites fluid, but not from Treg cells derived from the spleens of naive mice ( Figure S5 ). Perforin was not detected by flow cytometric methods in the same Treg cells and NK cells that were found to express granzyme B (data not shown), by means of an antibody that is capable of detecting perforin in NK cells activated in vitro, and NK cells isolated from MCMV-infected mice (Fehniger et al., 2007) . However, the sensitivity of this antibody was relatively low, because we have shown that cells expressing minimal amounts of perforin (as defined by this antibody) are still capable of killing target cells in a perforin-dependent fashion (Fehniger et al., 2007) .
Enhanced Clearance of a Syngeneic Tumor Cell Line in Treg Cell-Depleted Mice
To determine whether the enhanced tumor clearance in Gzmb À/À mice is also observed with a syngeneic tumor challenge, we developed a tumor cell line from 129/SvJ mice, via an established retroviral transduction strategy (Luo et al., 2005) . In brief, bone-marrow cells harvested from two female 129/SvJ mice were transduced with an MSCV-Myc-IRES-Bcl2 construct as described (Luo et al., 2005) . Myc-Bcl2 immortalized cells ( Because MB0 cells overexpress Bcl-2, and because granzyme B-induced target cell death is inhibited by Bcl-2 (Goping et al., 2003; Jans et al., 1999; Sutton et al., 2003) , this cell line is expected to be relatively resistant to granzyme B-mediated killing. We would predict that if granzyme B was relevant only in the NK and/or CD8 + T cell effector arm, granzyme B deficiency would have a minimal impact on the clearance of MB0 cells in vivo. Instead, we found that Gzmb À/À mice cleared MB0 cells more efficiently than did WT mice, consistent with a predominant effect of granzyme B in the Treg cell compartment ( Figures  4C and 4D ).
Adoptively Transferred Treg Cells Suppress Tumor Clearance in a Granzyme B-and PerforinDependent Fashion
To directly monitor tumor cell clearance in vivo, we transduced RMAS cells with a retroviral vector containing a click beetle red (CBR) luciferase-GFP fusion cDNA, and we used bioluminescence imaging to serially monitor mice injected intraperitoneally with these cells ( Figure 5A ). With this method, we quantified the clearance of RMAS cells in vivo and found that Gzmb À/À mice cleared RMAS cells more rapidly than did WT mice. As predicted, Prf1 À/À mice and Gzma À/À Gzmb À/À mice exhibited a trend toward reduced tumor clearance ( Figure 5B ; Figure S6 ). Three independent luciferase-expressing RMAS clones were completely cleared in WT mice by day 14, even when 2-8 3 10 6 cells were injected (data not shown);
the transduced RMAS clones expressed high amounts of CBR luciferase and GFP, which presumably induced more potent rejection after the first week of tumor growth in the mice. However, the evaluation of tumor clearance during the early phase (days 0-7) of the antitumor response ( Figure 5B ; Figure S6 ) in the various knockout strains correlated well with the survival curves of the mice receiving the nontransduced RMAS cells (Figures 1A and 1B) . MB0 cells were resistant to secondary viral transductions with the luciferase-GFP retroviral vector and could not be further evaluated with this assay. Treg cells exhibited slightly delayed clearance (data not shown), and 2 3 10 6 Treg cells significantly suppressed RMAS clearance ( Figure 5C ). We performed three independent adoptive transfer experiments with identical conditions and pooled the data for analysis ( Figure 5C ). Adoptive transfer of WT Treg cells into Gzmb À/À mice restored tumor growth to about 40% of that observed in WT mice. Transfer of equal doses of Gzmb À/À Treg cells ( Figure 5C ) or Prf1 À/À Treg cells ( Figure 5D ) had no significant effect on tumor growth, suggesting that granzyme B and perforin are both required for Treg cell-mediated suppression of tumor clearance in this model system.
The adoptive transfer of 2 3 10 6 naive WT Treg cells showed no effect on the survival of Gzmb À/À mice; however, this dose of Treg cells produced only partial restoration of tumor growth. Because only small numbers of Treg cells could be purified from naive spleens (about 7 3 10 5 cells per spleen), we were not able to purify adequate numbers of cells for a large study designed to assess survival outcomes.
NK and CD8 + T Cell Death in Tumor Ascites Is Treg Cell Dependent
We hypothesized that NK and CD8 + T cells might be ''suppressed'' by being killed by Treg cells in the tumor environment. To test this hypothesis, we performed ex vivo experiments to assess NK and T cell death in tumor ascites fluid. We collected tumor ascites fluid from WT mice, Prf1 À/À mice, and Gzmb À/À mice 5 days after i.p. injection of RMAS cells and immediately stained the cells with 7-AAD to assess cell death. Fewer than 5% of DX5 + CD3 À NK cells or CD8 + T cells in the tumor ascites fluid of all three genotypes were 7-AAD positive (data not shown). Because the ingestion of apoptotic cells by peritoneal macrophages could potentially mask our ability to detect apoptotic cells in vivo, we decided to first deplete adherent cells by incubating the tumor ascites fluid on tissue culture plates for 40 min at 37 C (Kobayashi et al., 1990; Law et al., 1989) . The nonadherent cells were either directly stained with 7-AAD at time 0 or incubated for 3 hr at 37 C before 7-AAD staining. Immediately after depletion of adherent cells, fewer than 5% of NK or T cells in the tumor ascites of all three genotypes were 7-AAD positive (data not shown); after the 3 hr incubation, however, about 30% of NK and CD8 + T cells in the tumor ascites of WT mice became 7-AAD positive ( Figures 6A-6C ). Importantly, NK and CD8 + T cell death was (Figures 6B and 6C ). To assess background cell death in this system, we isolated control peritoneal fluids from naive, noninjected WT mice (n = 3), Gzmb À/À mice (n = 3), and Prf1 À/À mice (n = 3); spontaneous 7-AAD positivity in the control peritoneal fluids (for all three genotypes) was consistently low for NK cells (6.8% ± 1%, n = 9), CD8 + T cells (6.3% ± 1.6%, n = 9), and Treg cells (4.8% ± 1.5%, n = 9). To 
Gzmb
À/À mice, and Prf1 À/À mice were difficult to compare at any given time, because the numbers of tumor cells in the ascites fluid of these mice were so drastically different (Figures 5B and 6A ; Figure S6 ). et al., 2006) . Neither of these studies specifically addressed the role of the perforin-granzyme pathway for Treg cell-mediated NK suppression in these experimental settings. However, it is important to note that TGF-b can influence the expression of perforin and granzymes, thereby altering the function of cytotoxic lymphocytes (Thomas and Massague, 2005) . The effect of TGF-b on perforin and granzyme expression in Treg cells has not yet been defined but is under investigation. In the model systems described in this study, granzyme B and perforin were shown to be important for the ability of Treg cells to suppress NK and CD8 + T cell activity.
Recent studies from our laboratory and others have suggested that human and mouse Treg cells can use the (C) A summary of pooled data from three independent experiments is shown (n = 2 in each experimental group, 6 total mice). Spontaneous death of NK cells (6.8% ± 1%, n = 9), of Treg cells (4.8% ± 1.5%, n = 9), and of CD8 + T cells (6.3% ± 1.6%, n = 9) in the noninjected control peritoneal fluid was subtracted to provide specific cytotoxicity data. Data points are shown as mean ± SEM, and two-tailed t tests were used to determine statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001). perforin-granzyme pathway to kill target cells as a mechanism of suppression (Grossman et al., 2004a; Zhao et al., 2006) . Previous reports also demonstrated the expression of granzyme B in purified murine CD4 + CD25 + Treg cells that were activated in vitro by TCR ligation and IL-2 (Gondek et al., 2005; Zhao et al., 2006) . However, as noted above, several different mechanisms are potentially relevant for Treg cell-mediated immune suppression, including cytokine-mediated (e.g., TGF-b, IL-10) as well as cell-surface molecule-dependent inhibition of T cells and APCs (e.g., GITR and CTLA4) (von Boehmer, 2005; Zou, 2006) . The exact contribution of each pathway to overall Treg suppressive activity may be context and/or model dependent; however, it is also possible that Treg cells may use several mechanisms simultaneously to provide ''fail-safe'' suppression of activated immune cells, which can damage the host if uncontrolled.
Our studies suggest that Treg cells may suppress NK and CD8 + T cells by killing them. The system that we used to demonstrate this finding relies upon the activation of T cells and NK cells in vivo, followed by depletion of adherent cells (to prevent the ingestion of newly apoptotic cells), followed by ex vivo incubation to allow the activated cells to interact. The day 5 ascites fluid contains a complex mixture of cells, but it is probable that NK and CD8 + T cell death in this setting is Treg cell dependent (because depletion of Treg cells with the PC61 CD25 antibody reduces NK and CD8 + T cell death). Further, our data suggest that both granzyme B and perforin are relevant for this phenotype, because deficiency of either reduces NK and CD8 + T cell death. However, the reduction in NK and CD8 + T cell death was not as pronounced with perforin or granzyme B deficiency as it was with Treg cell depletion, suggesting that Treg cells must use additional pathways to cause suppression and/or death to NK and CD8 + T cells. shown that granzyme B plays a major role in the ability of IL-15-activated NK cells to kill their targets (Fehniger et al., 2007) ; however, the in vivo activation of NK and CD8 + T cells by tumors may invoke additional killing pathways. Indeed, granzyme B-independent mechanisms are clearly capable of providing NK cell-mediated tumor clearance (Grundy et al., 2007; Rosen et al., 2000; Screpanti et al., 2001) .
In summary, the perforin-granzyme pathway is important not only for the function of NK and CD8 + T cells, but it may also be utilized by Treg cells to suppress the activity of these same cells (Figure 7 ). It will be important to determine whether Treg cells can use the perforingranzyme B pathway to suppress other immune cells in vivo, such as CD4 + CD25 À T cells and B cells; alternative model systems will be required to address these questions in the future.
EXPERIMENTAL PROCEDURES
Animals and Tumor Cell Lines WT 129/SvJ mice were obtained from the Jackson Laboratory. Gzma À/À mice were generated as described (Shresta et al., 1997) . Gzmb À/À mice were generated as described (Heusel et al., 1994; Revell et al., 2005) . Both Gzma À/À mice and Gzmb À/À mice were generated and maintained in congenic 129/SvJ mice (H-2
mice were generated by crossing Gzma À/À mice with Gzmb À/À mice, followed by genotyping with Southern and PCR strategies. Prf1
mice were developed by a speed congenic strategy to backcross B6J mice containing the ''Kagi'' mutation to 129/SvJ mice for eight generations; >98% of the congenic markers tested were from the 129/SvJ strain in the mice that were used to generate the breeding colony of these mice. RMAS lymphoma and B16 melanoma cell lines, which were originally derived from C57BL/6 mice (H-2 b , I-A b ), were obtained from W. Yokoyama and maintained in complete K10 medium (Fehniger et al., 2007) . The MB0 acute myeloid leukemia (AML) cell line was developed from 129/SvJ mice by an established retroviral transduction strategy (Luo et al., 2005) . In brief, bone-marrow cells harvested from two female 129/SvJ mice were transduced with an MSCVMyc-IRES-Bcl2 construct as described (Luo et al., 2005) . Myc-Bcl2 immortalized cells (MB0) were passaged in regular K10 medium (without additional growth factors) for 3 months before injection for survival and granzyme expression studies. All mice were bred and maintained in SPF housing, and all experiments were conducted in accordance with Washington University School of Medicine animal care guidelines, via protocols approved by the animal studies committee.
Reagents and Antibodies
The anti-asialo GM1 antiserum was purchased from Wako Chemicals. The purified CD25 antibody (PC61) and rat IgG1 isotype control (HRPN), CD8 antibody (53-6.7), and rat IgG2a isotype control (C1.18) were purchased from Bio Express. The CD4 + CD25 + Treg isolation kits were purchased from Miltenyi Biotec. Antibodies used include anti-mouse CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD25 (7D4, PC61), CD49b (DX5), CD16/32 (2.4G2), Bcl-2 (3F11) (BD Biosciences), Foxp3 (eBioscience, FJK-16 s), and granzyme B (Caltag, GB12). The anti-mouse granzyme A monoclonal antibody was produced in our laboratory and is now available from Santa Cruz (3G8.5).
Tumor Challenge and Survival Study
Tumor cells were washed twice in RPMI 1640 by centrifuging for 5 min at 300 3 g and were then resuspended in RPMI 1640 at appropriate concentrations. For survival studies, all WT mice, Gzm À/À mice, and Prf1 À/À mice were injected in the lateral tail vein with 1 3 10 5 , 2 3 10 5 , or 2.5 3 10 5 RMAS lymphoma cells, or 2 3 10 5 or 3 3 10 5 B16 melanoma cells in 200 ml RPMI 1640 on day 0. All mice were monitored over a 60 day period. For the MB0 tumor challenge, mice were injected i.p. with 5 3 10 5 or 1 3 10 6 cells. Mice were sacrificed when they gained more than 25% body weight and/or become moribund. To determine the impact of Treg cell depletion on survival, 500 mg of purified PC61 CD25 monoclonal antibody (or rat IgG1 isotype control) was administered by intraperitoneal injection 2 days prior to tumor injection and readministered weekly during the course of the experiment. CD8 monoclonal antibody (53-6.7) or rat IgG2a isotype control was administered similarly to determine its effect on the survival of mice challenged with RMAS cells. Kaplan-Meier survival analysis was performed with Prism software (Graph Pad, San Diego, CA).
Cell Isolation
Lymphocytes were isolated from the tumor environment, which includes ascites fluid after i.p. tumor injection or tumor-infiltrated livers and/or lungs after i.v. tumor injection and the spleens and peripheral lymph nodes of tumor-bearing mice (which were not infiltrated by tumor cells). As controls, the peritoneal fluid, spleens, livers, and lungs of naive mice were also collected as described (Grossman et al., 2004b; Heusel et al., 1994; Revell et al., 2005) .
Intracellular Staining and Flow Cytometry 1 3 10 6 cells were washed and resuspended in staining buffer (PBS, 0.5% bovine serum albumin, 0.5 mM EDTA). Samples were labeled with primary-conjugated antibodies against cell-surface markers (anti-mouse CD3, CD4, CD8, CD25, DX5) (BD Biosciences). Samples were fixed, permeabilized (Foxp3 staining kit, eBioscience), and stained with primary-conjugated anti-granzyme A antibody (3G8.5; Santa Cruz), and/or primary-conjugated anti-granzyme B antibody (GB12; Caltag), and/or primary-conjugated anti-Foxp3 antibody (FJK-16 s; eBioscience) diluted at 1:400 in staining buffer. Sample data were acquired on a Cytek-modified FACScan (Becton Dickinson) or FC500 (Coulter) flow cytometer and analyzed with CXP (Coulter) or FlowJo (TreeStar) software. Isotype controls were used to set quadrant and regional gates. All flow cytometric analyses depicted are representative of five or more mice. Anti-granzyme A and anti-granzyme B antibodies were analyzed for antigen specificity by knockout mouse staining assays as described (Fehniger et al., 2007; Grossman et al., 2004b) .
Bioluminescence Imaging of In Vivo Tumor Clearance RMAS cells were transduced with a DU3 retroviral construct that drives the expression of a fusion cDNA encoding click beetle red luciferase (CBR) and green fluorescence protein (GFP). Individual GFP-positive RMAS cells were MoFlo sorted into single wells of a 96-well plate. The expanded clones were further screened for high luciferase expression. CBR luciferase-expressing RMAS clones were injected i.p. into WT mice, Gzm À/À mice, and Prf1 À/À mice in 200 ml RPMI 1640 on day 0, and bioluminescence imaging was performed 2 hr later and variously on days 2 through 21 after injection. For imaging, mice were injected i.p. with D-luciferin (150 mg/g body weight), anesthetized (2% isoflurane), and placed in an IVIS 50 imaging system (Xenogen) (exposure time, 1-30 s; binning, 2-8; no filter; f/stop, 1; FOV, 12 cm) (Gross and Piwnica-Worms, 2005) . Regions of interest (ROI) were defined manually over the whole body with Living-Image software (Igor Wavemetrics) for determining tumor burden signal intensities. Data were expressed as photon flux (photons/s) or change from initial (post injection image/2 hr image) across all mice receiving the same treatment. Bioluminescence imaging was performed to serially assess tumor clearance.
Flow-Based Ex Vivo NK and CD8 + T Cell Death Assay WT mice, Gzmb À/À mice, and Prf1 À/À mice were depleted of Treg cells by intraperitoneal injection of 500 mg of PC61 CD25 monoclonal antibody (or rat IgG1 control antibody) on day 4 and day 2 prior to intraperitoneal injection of 1 3 10 6 RMAS cells. On day 5 after tumor injection, tumor ascites fluid was harvested. To prevent the phagocytosis of apoptotic cells, the ascites fluid was depleted of adherent cells by incubating total ascites fluid on plastic tissue-culture plates for 40 min (Kobayashi et al., 1990; Law et al., 1989) . As a negative control, peritoneal fluid was isolated from naive, noninjected WT mice, Gzmb À/À mice, and Prf1 À/À mice, and treated identically. Nonadherent cells were harvested and incubated in V-bottom 96-well plates for 3 hr, followed by staining with primary-conjugated antibodies against cell-surface markers (CD3, CD4, CD8, CD25 [7D4], DX5) and 7-AAD to assess cell death in the NK, CD8 + T, and Treg compartments by flow cytometry. Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P.E., Novault, S., Escudier, B., Vivier, E., et al. (2005) . 
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